bDMARDs Quick Reference Guide



Active ingredient


Mechanism of action

Interleukin (IL) -23 inhibitor

Molecule type

IgG monoclonal antibody (humanised)

PBS listed indications

Severe chronic plaque psoriasis

Reference product (brand)


Biosimilar brands


Administration information

Mode of administration

Subcutaneous injection

Administration devices and strengths

Pre-filled syringe 75mg/0.83mL

Instructions for patient self-administration are available from

A QR code that can be scanned for more information is also available on the packaging.

Frequency of administration

Every 12 weeks (maintenance)


Store at 2-8oC (refrigerate do not freeze).

Keep pre-filled syringes in the outer carton until time of use to protect from light.

For a more comfortable injection, patients may remove the carton from the refrigerator before injecting and allow to reach room temperature (15-30 minutes) out of direct sunlight without removing the pre-filled syringes from the outer carton.

Standard dosing

150mg (2 x 75mg injections) at week 0 and week 4, then every 12 weeks thereafter.

The two injections should be administered at least 3cm apart.

Special notes

Risankizumab has the potential to reactivate latent TB (begin TB treatment before starting).
Patients with suspected latent or active TB should be treated in consultation with an Infectious Diseases physician.

Risankizumab may increase the risk of infection. Treatment should not be initiated in patients with clinically significant active infection until the infection resolves or is adequately treated.


Live vaccines should not be given concurrently with risankizumab.


Pharmaceutical benefits Scheme (PBS) listing. Available from [accessed 8/10/21]

Product information. Available from [accessed 11/5/21]

Australian Medicines Handbook 2020 (online). Adelaide: Australian Medicines Handbook Pty Ltd; 2020 July. Available from: